Raymond James Financial’s Ionis Pharmaceuticals IONS Stock Holding History

Raymond James Financial’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.8M	Buy	237,348 +2,227	+0.9%	+$168K	0.01%	1603
2026 Q1	$17.7M	Sell	235,121 -22,089	-9%	-$1.74M	0.01%	1569
2025 Q4	$20.3M	Buy	257,210 +16,786	+7%	+$1.26M	0.01%	1430
2025 Q3	$15.7M	Buy	240,424 +29,832	+14%	+$1.46M	0.01%	1587
2025 Q2	$8.32M	Buy	210,592 +61,902	+42%	+$2.03M	﹤0.01%	2005
2025 Q1	$4.49M	Buy	148,690 +43,071	+41%	+$1.41M	﹤0.01%	2405
2024 Q4	$3.69M	Buy	+105,619	New	+$3.95M	﹤0.01%	2523

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Raymond James Financial's IONS Position: Q2 2026 in Review

Raymond James Financial increased its Ionis Pharmaceuticals (IONS) stake by 0.95% in Q2 2026, buying an estimated $168K and bringing the position to 237,348 shares worth $18.8M. The position accounts for 0.01% of the portfolio, ranked #1603.

Raymond James Financial first reported a position in IONS in Q4 2024 and has held it in 7 quarters since. The position peaked at $20.3M in Q4 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Raymond James Financial held 237,348 shares of Ionis Pharmaceuticals worth $18.8M as of Q2 2026.
Raymond James Financial bought 2,227 Ionis Pharmaceuticals shares in Q2 2026, an estimated $168K.
Ionis Pharmaceuticals made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #1603 holding.
Raymond James Financial first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Ionis Pharmaceuticals position peaked at $20.3M in Q4 2025.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.